
Immix Biopharma Investor Relations Material
Latest events

Status Update
Immix Biopharma

Q2 2025
8 Aug, 2025

Corporate Presentation
30 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immix Biopharma Inc
Access all reports
Immix Biopharma Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases. The company’s lead programs are based on its proprietary tissue-specific therapeutics platform, designed to deliver biologics and small molecules to specific tissues while minimizing systemic toxicity. Immix Biopharma conducts clinical trials for rare and hard-to-treat cancers, as well as immune-related conditions. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Key slides for Immix Biopharma Inc


Investor Presentation
Immix Biopharma Inc


Corporate Presentation
Immix Biopharma Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IMMX
Country
🇺🇸 United States